meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic, hormone-sensitive prostate cancer
11
renal cell cancer (RCC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
avelumab based treatment
avelumab plus axitinib
nivolumab based treatment
nivolumab alone
nivolumab plus cabozantinib
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus axitinib
pembrolizumab plus lenvatinib
Immune checkpoint association
nivolumab plus ipilimumab
mTOR inhibitors
everolimus
lenvatinib plus everolimus
VEGF(R) inhibitor
lenvatinib
lenvatinib in association
versus all
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs nivolumab based treatment
vs nivolumab alone
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs mTOR inhibitors
vs everolimus
vs non active control
vs no additional treatment
vs placebo
vs VEGF(R) inhibitor
vs pazopanib
vs sunitinib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
nivolumab based treatment
nivolumab alone
nivolumab plus cabozantinib
Comparator:
vs nivolumab plus ipilimumab;
vs sunitinib;
vs everolimus;
Risk of bias:
low;
some concerns;
high;
NA;